|
|
|
Insider
Information: |
Hack Andrew A. F. |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
25,181 |
|
Indirect Shares
|
18,379,099 |
|
|
Direct
Value |
$165,994 |
|
|
Indirect Value
|
$36,524,494 |
|
|
Total
Shares |
18,404,280 |
|
|
Total
Value |
$36,690,488 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
20
|
7
|
Stock
price went up :
|
17
|
3
|
Stock
price went down : |
3
|
4
|
|
|
|
Gain/Loss Ratio : |
5.7
|
5.7
|
Percentage
Gain/Loss : |
61.2%
|
-72.1%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Editas Medicine, Inc. |
EDIT |
Chief Financial Officer |
2019-02-04 |
0 |
2017-02-15 |
0 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
|
2023-08-08 |
10,714 |
2023-08-08 |
915,000 |
Premium* |
|
Mersana Therapeutics, Inc. |
MRSN |
Director |
2023-06-08 |
14,467 |
2023-06-08 |
8,663,673 |
Premium* |
|
Bcls Acquisition Corp. |
BLSA |
Chief Financial Office... |
2020-10-26 |
0 |
2020-10-26 |
487,500 |
Premium* |
|
Atea Pharmaceuticals, Inc. |
AVIR |
Director |
2020-11-03 |
0 |
2020-11-03 |
5,615,659 |
Premium* |
|
Nuvalent, Inc. |
NUVL |
|
2021-08-02 |
0 |
2024-03-27 |
2,697,267 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-03-20 |
4 |
AS |
$37.51 |
$1,059,960 |
D/D |
(28,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-06-01 |
4 |
AS |
$39.05 |
$274,970 |
D/D |
(7,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-06-01 |
4 |
OE |
$6.48 |
$45,360 |
D/D |
7,000 |
2,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-06-04 |
4 |
OE |
$24.60 |
$73,800 |
D/D |
3,000 |
3,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-06-04 |
4 |
AS |
$37.10 |
$111,300 |
D/D |
(3,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-08-31 |
4 |
AS |
$32.23 |
$322,300 |
D/D |
(10,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-08-31 |
4 |
OE |
$6.48 |
$64,800 |
D/D |
10,000 |
10,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-09-28 |
4 |
OE |
$6.48 |
$51,840 |
D/D |
8,000 |
8,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-09-28 |
4 |
AS |
$32.08 |
$256,640 |
D/D |
(8,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-10-26 |
4 |
AS |
$25.70 |
$154,200 |
D/D |
(6,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-10-26 |
4 |
OE |
$6.48 |
$38,880 |
D/D |
6,000 |
6,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-11-23 |
4 |
OE |
$6.48 |
$34,240 |
D/D |
5,284 |
5,284 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2018-11-23 |
4 |
AS |
$28.14 |
$148,739 |
D/D |
(5,284) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2019-01-04 |
4 |
OE |
$6.48 |
$45,360 |
D/D |
7,000 |
7,000 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2019-01-04 |
4 |
AS |
$22.48 |
$157,360 |
D/D |
(7,000) |
0 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2019-02-04 |
4 |
OE |
$6.48 |
$44,680 |
D/D |
6,895 |
6,895 |
0 |
- |
|
EDIT |
Editas Medicine, Inc. |
Chief Financial Officer |
|
2019-02-04 |
4 |
AS |
$21.39 |
$147,484 |
D/D |
(6,895) |
0 |
0 |
- |
|
BLSA |
Bcls Acquisition Corp. |
Chief Financial Officer |
|
2020-10-26 |
4 |
A |
$10.00 |
$4,875,000 |
I/I |
487,500 |
487,500 |
0 |
- |
|
DVAX |
Dynavax Technologies Corp |
Director |
|
2019-08-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,525,000 |
|
- |
|
MRSN |
Mersana Therapeutics, Inc... |
Director |
|
2020-04-07 |
4 |
B |
$5.59 |
$20,649,463 |
I/I |
3,445,667 |
3,445,667 |
2.1 |
% |
|
DVAX |
Dynavax Technologies Corp |
Director |
|
2020-05-27 |
4 |
B |
$5.00 |
$5,000,000 |
I/I |
1,000,000 |
8,525,000 |
2.1 |
% |
|
AVIR |
Atea Pharmaceuticals, Inc... |
Director |
|
2020-11-03 |
4 |
B |
$24.00 |
$6,000,000 |
I/I |
250,000 |
5,615,659 |
2.1 |
- |
|
AVIR |
Atea Pharmaceuticals, Inc... |
Director |
|
2020-11-03 |
4 |
A |
$0.00 |
$0 |
I/I |
5,365,659 |
5,365,659 |
0 |
- |
|
MRSN |
Mersana Therapeutics, Inc... |
Director |
|
2021-01-08 |
4 |
B |
$18.39 |
$1,839,000 |
I/I |
100,000 |
3,545,667 |
2.1 |
% |
|
MRSN |
Mersana Therapeutics, Inc... |
Director |
|
2021-01-11 |
4 |
B |
$18.52 |
$1,389,000 |
I/I |
75,000 |
3,620,667 |
2.1 |
% |
|
80 Records found
|
|
Page 2 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|